Cordis wins FDA approval for sirolimus-eluting balloon
Published . Updated .
The approval gives physicians an alternative to uncoated balloons and Boston Scientific’s paclitaxel-coated device.
Directly affected
- BSX Boston Scientific
Named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The approval gives physicians an alternative to uncoated balloons and Boston Scientific’s paclitaxel-coated device.
Source: MedTech Dive
How far Boston Scientific (BSX) has moved since 22 Sep 2026
Since the first closing price after “Cordis wins FDA approval for sirolimus-eluting balloon,” Boston Scientific (BSX) is +0.87%. The S&P 500 fund (SPY) is -0.17% over the same days, a +1.05% difference versus the market.
Official trades in Boston Scientific (BSX) around 22 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 7 days after publication, inside 30 days. The filing is listed beside the story “Cordis wins FDA approval for sirolimus-eluting balloon.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 11 days before publication, inside 30 days. The filing is listed beside the story “Cordis wins FDA approval for sirolimus-eluting balloon.”
- Kevin Hern sell Boston Scientific (BSX) ($50,001 - $100,000). That is 13 days before publication, inside 30 days. The filing is listed beside the story “Cordis wins FDA approval for sirolimus-eluting balloon.”
- Kevin Hern sell Boston Scientific (BSX) ($50,001 - $100,000). That is 18 days before publication, inside 30 days. The filing is listed beside the story “Cordis wins FDA approval for sirolimus-eluting balloon.”
- Kevin Hern sell Boston Scientific (BSX) ($1,001 - $15,000). That is 19 days before publication, inside 30 days. The filing is listed beside the story “Cordis wins FDA approval for sirolimus-eluting balloon.”
- Kevin Hern sell Boston Scientific (BSX) ($15,001 - $50,000). That is 22 days before publication, inside 30 days. The filing is listed beside the story “Cordis wins FDA approval for sirolimus-eluting balloon.”
- Donald J Trump buy Boston Scientific (BSX) ($15,001 - $50,000). That is 25 days before publication, inside 30 days. The filing is listed beside the story “Cordis wins FDA approval for sirolimus-eluting balloon.”
- Gilbert Cisneros buy Boston Scientific (BSX) ($1,001 - $15,000). That is 35 days before publication, inside 60 days. The filing is listed beside the story “Cordis wins FDA approval for sirolimus-eluting balloon.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who is named in “Cordis wins FDA approval for sirolimus-eluting balloon”
Companies carried with this story
- BSX Boston Scientific
Boston Scientific (BSX) is linked, with no stored direction, high confidence in the 22 Sep 2026 story “Cordis wins FDA approval for sirolimus-eluting balloon.” Reason on file: The reported development directly names BOSTON SCIENTIFIC CORP in the summary; GA resolved that company to BSX
- ACHC Acadia Healthcare
For “Cordis wins FDA approval for sirolimus-eluting balloon,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
For “Cordis wins FDA approval for sirolimus-eluting balloon,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
For “Cordis wins FDA approval for sirolimus-eluting balloon,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence in the 22 Sep 2026 story “Cordis wins FDA approval for sirolimus-eluting balloon.” Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
For “Cordis wins FDA approval for sirolimus-eluting balloon,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
For “Cordis wins FDA approval for sirolimus-eluting balloon,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
How “Cordis wins FDA approval for sirolimus-eluting balloon” reaches Boston Scientific (BSX)
The 22 Sep 2026 story “Cordis wins FDA approval for sirolimus-eluting balloon” names Boston Scientific (BSX) because of this story.
For Boston Scientific (BSX), the reason on file says The reported development directly names BOSTON SCIENTIFIC CORP in the summary; GA resolved that company to BSX
Also listed, Acadia Healthcare (ACHC): GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Price levels for Boston Scientific (BSX)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. BSX traded between 41.39 and 45.74 across 20 sessions. The latest close on file is 45.05.
A simple score for Boston Scientific (BSX)
46 out of 100
“Cordis wins FDA approval for sirolimus-eluting balloon” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.